Replies to post #131285 on Biotech Values

[BTH]

It could be a good stock to own around here. If all the momentum guys are bailing (or already are out) playing the run-up to approval, if the drug becomes a big seller it should add nicely to price of the stock.

[pcrutch]

I know Oppenheimer, Citi and JP Morgan all came out with very positive notes on them. Many were surprised at the price(not sure how given the recent trend), originally modeled around $40-60K/year. Everyone likes the upside in the label.

Do you see any upside down the road in any other hematologic disorders besides MPN's? I know theyre running a trial in patients with relapsed/refractory multiple myeloma, AML, ALL, and MDS, and blast phase or tyrosine kinase refractory CML. There could be more upside if any of these pan out, but not counting on it.

[mcbio]

Their RA drug is significant I think.

I think so as well and INCY has nice terms on their deal with LLY IMO. I've always followed RIGL and do like fostamatinib but INCY's drug seems to have less questions at this point on the safety front and I think efficacy is reasonably comparable between the two drugs at this point.

Do you have any opinion on the other drugs in INCY's pipeline, namely the c-MET drug in Phase 1 and the IDO inhibitor in Phase 1? The latter sounds like a novel candidate; don't know what the expectations are for success here. In terms of the c-MET candidate, I wonder to what extent, if any, INCY's drug is differentiated from EXEL and ARQL's c-MET drugs that are much further along.

[JJM760]

Incy is getting cheaper by the day. If it dips below $12, I might have to sell some Ariad and buy it ;0)